Sartorius Stedim Biotech Reports Share and Voting Rights Details

Sartorius Stedim Biotech SA has released its latest figures concerning shares and voting rights. As of March 31, 2026, the company reports a total of 97,330,405 shares constituting its issued capital. The declaration indicates a total of 164,793,507 theoretical voting rights, which includes treasury shares held by the company. The net voting rights available to shareholders number 164,741,373. This regulatory disclosure complies with French financial market rules, specifically Article L 233-8-II of the Code of commerce and Article 223-6 of the AMF’s general regulations.

The information from this report was disseminated by EQS Group, confirming the transparency and due diligence of Sartorius Stedim Biotech in financial reporting. The company remains a key player in the biotech arena, with its base in Aubagne, France. Interested parties can acquire further details from the company’s website or contact them directly through provided communication channels.